ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and RENAL FAILURE

Overview

RENAL FAILURE is the #7 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 2,086 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to RENAL FAILURE. This represents approximately 4.8% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience renal failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RENAL FAILURE is moderately reported among ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to renal failure, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

• BONE DENSITY DECREASED — 4,492 reports
• CHRONIC KIDNEY DISEASE — 2,605 reports
• BONE LOSS — 2,410 reports
• OSTEONECROSIS — 2,378 reports
• TOOTH LOSS — 2,247 reports
• MULTIPLE FRACTURES — 2,131 reports
• OSTEOPOROSIS — 1,928 reports
• RENAL INJURY — 1,916 reports
• PAIN — 1,857 reports
• EMOTIONAL DISTRESS — 1,803 reports

Other Drugs Associated with RENAL FAILURE

The following drugs have also been linked to renal failure in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause RENAL FAILURE?

RENAL FAILURE has been reported as an adverse event in 2,086 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RENAL FAILURE with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

RENAL FAILURE accounts for approximately 4.8% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.

What should I do if I experience RENAL FAILURE while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience renal failure while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages